June 2019: Will T-Mobile's Sprint call connect? Plus how Abbvie's Allergan deal is giving shareholders wrinkles

from Rangeley Capital Podcast · host Rangeley Capital Podcast

Following a month of blockbuster M&A, the Rangeley team discusses how Abbvie's deal is giving their shareholders stress wrinkles. Then, they talk about the Sprint / T-Mobile deal as it (apparently) nears DOJ approval.

Episode metadata supplied by the publisher feed · Published Jun 28, 2019

Embed this episode

Attribution link and audio player

NOW PLAYING

June 2019: Will T-Mobile's Sprint call connect? Plus how Abbvie's Allergan deal is giving shareholders wrinkles

0:00 22:22

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Rangeley Capital Podcast?

This episode is 22 minutes long.

When was this Rangeley Capital Podcast episode published?

This episode was published on June 28, 2019.

Can I download this Rangeley Capital Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!